Skip to main content

EDITORIAL article

Front. Pharmacol., 06 August 2020
Sec. Neuropharmacology
This article is part of the Research Topic The Role of Heat Shock Proteins in Neuroprotection View all 5 articles

Editorial: The Role of Heat Shock Proteins in Neuroprotection

  • 1Biological Research Centre, Hungarian Academy of Sciences (MTA), Szeged, Hungary
  • 2Montreal Neurological Institute, McGill University, Montreal, QC, Canada
  • 3Biochemistry and Biomedicine, University of Sussex, Brighton, United Kingdom

This Research Topic covers an increasingly important topic on the “Role of Heat Shock Proteins in Neuroprotection”. With a growing elderly population and an ever-increasing amount of resources required to treat neurodegeneration, there is a growing demand for solutions. Chaperone systems represent the major pro-survival strategy for cells of living organisms in response to stress. Heat shock proteins are associated with neurological disease because they can suppress or promote the aggregation of misfolded toxic proteins. This Research Topic brings together a number of selected articles that show how diverse heat shock proteins impact on neurodegenerative disease.

The review by Webster et al. discusses the role that misfolding, aggregation, and aberrant accumulation of proteins play as a central component in the progression of neurodegenerative disease. While molecular chaperones are normally protective, they can also promote the stabilization of toxic protein aggregates, which can lead to neurodegenerative disease. The authors review the role by which sHsps modulate neurodegenerative disease-relevant protein aggregation.

The manuscript by Gracia et al. looks at the therapeutic potential of the Hsp90/Cdc37 interaction in neurodegenerative disease, such as Alzheimer’s, Huntington’s, and Parkinson’s. This article presents evidence that client proteins, and in particular kinases, may be differentially affected when modulating the Hsp90/Cdc37 chaperone system, depending on the strength of their interaction with this chaperone complex. Consequently, this may allow therapeutic intervention by targeting Hsp90/Cdc37-client protein complexes, which are currently underexplored.

The role of heat shock protein’s in neuroinflammation is discussed by Dukay et al. Apart from the classical molecular chaperoning of heat shock proteins, they are shown to play a role in neurological disorders by modulating neuronal survival, inflammation, and disease-specific signalling processes. Although the processes of neuro-inflammation are not yet fully understood, the authors explore the existing literature on the inflammatory function of heat-shock-proteins within the central nervous system.

Cristofani et al. then investigates the role of HSPB8 on the protein quality control system of cells. This system prevents the deleterious effects of misfolded proteins of which HSPB8 is a component. Elevated levels of HSPB8, activated by misfolded proteins through transcription, contribute to preventing the aggregation of misfolded proteins, facilitate autophagy, and enable the efficient clearance of the misfolded proteins.

In conclusion, the Research Topic brings together some important topics showing how heat shock proteins are central to many neurological disease processes and how intervention by modulating the expression of the chaperone system can be used for therapeutic treatment. It stands as an introduction to an emerging field to stimulate research on chaperones as targets for neuroprotection.

Author Contributions

CP wrote and all authors edited the editorial. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: heat shock protein, neuroprotection, neurodegeneration, chaperone, protein aggregation

Citation: Santha M, Durham HD, Vigh L and Prodromou C (2020) Editorial: The Role of Heat Shock Proteins in Neuroprotection. Front. Pharmacol. 11:1227. doi: 10.3389/fphar.2020.01227

Received: 23 June 2020; Accepted: 27 July 2020;
Published: 06 August 2020.

Edited and reviewed by: Nicholas M. Barnes, University of Birmingham, United Kingdom

Copyright © 2020 Santha, Durham, Vigh and Prodromou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chrisostomos Prodromou, chris.prodromou@sussex.ac.uk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.